Determination of Equilibrium Constants of Glibenclamide-Human Serum Albumin Interactions by High-Performance Affinity Chromatography
Sophia How
Author
07/28/2020
Added
22
Plays
Description
The interaction between glibenclamide and HSA in normal and modified form of proteins.
Searchable Transcript
Toggle between list and paragraph view.
- [00:00:00.000]Hi everyone. My name is Sophia How.
- [00:00:02.190]And I'll be presenting my project on
- [00:00:04.270]Determination of Equilibrium Constant of
- [00:00:06.619]Glibenclamide- Human Serum Albumin
- [00:00:08.940]Interaction by High-Performance Affinity
- [00:00:10.624]Chromatography.
- [00:00:11.803]In 2018, approximately 10.5% of the
- [00:00:14.869]population, or 34.2 million people in the
- [00:00:18.229]United States were diagnosed with Type II
- [00:00:20.151]diabetes. Type II diabetes is a metabolic
- [00:00:22.426]disorder in which the pancreas does not
- [00:00:24.876]produce enough insulin. It is most common
- [00:00:27.818]form of diabetes, affecting 90-95% of the
- [00:00:32.068]patients who have the condition.
- [00:00:34.098]Human Serum Albumin as HSA is the most
- [00:00:37.581]abundant transport protein with two major
- [00:00:40.566]drug binding sites shown in Figure 1 that
- [00:00:42.912]demonstrate the two sites- Sudlow site 1
- [00:00:45.741]and 2 which R-warfarin and L-tryptophan
- [00:00:53.071]will bind with the HSA.
- [00:00:54.818]The glycation process in Figure 2
- [00:00:57.603]is when glucose and protein bind together
- [00:01:01.603]to form a Schiff’s base and it rearranged
- [00:01:06.013]to a more stable product- Amadori product.
- [00:01:08.927]Then it will undergoes oxidation,
- [00:01:12.467]dehydration or degradation to get Advanced
- [00:01:17.758]Glycation End-product as AGE modified HSA.
- [00:01:24.248]HSA in normal and modified forms will
- [00:01:27.558]bind with Glibenclamide, the drug shown in
- [00:01:31.238]Figure 3. It is a drug that treats with
- [00:01:34.551]Type II diabetes.
- [00:01:37.653]The goal of this study is to examine the
- [00:01:40.103]interaction of Glibenclamide with HSA in
- [00:01:44.178]its normal and various modified forms
- [00:01:47.916](methylglyoxal-AGE and glyoxal-AGE) of the
- [00:01:51.662]protein. The method shown in Figure 4,
- [00:01:56.592]shows the sample runs through the High
- [00:01:59.152]Performance Affinity Chromatography
- [00:02:02.594]as HPAC the sample will bind to the
- [00:02:07.470]binding agents and leftover with non-
- [00:02:11.470]retained sample will leave out. We will
- [00:02:15.871]be injecting the drug solution onto 10
- [00:02:19.871]millimters times 2.1 millimeters affinity
- [00:02:24.231]microcolumns. And the experiment were
- [00:02:26.918]carried at the flow rate of 0.5mL/min and
- [00:02:30.918]the temperature of 37 degree Celsius.
- [00:02:38.260]The R-warfarin and L-tryptophan were used
- [00:02:41.918]as a site-specific probe to examine the
- [00:02:44.418]HSA and its modified forms.
- [00:02:47.767]And we will be performing eight different
- [00:02:50.307]mobile phase concentrations from 0
- [00:02:52.686]micromolar to 20 micromolars.
- [00:02:58.686]The result shown in Figure 5 is that the
- [00:03:05.709]retention time on the x-axis versus the
- [00:03:09.050]absorbance of the probe being measured in
- [00:03:11.730]the interaction of glibenclamide and
- [00:03:13.921]l-tryptophan with concentrations ranging
- [00:03:18.150]from 0 micromolar to 20 micromolars.
- [00:03:22.597]Using Figure 5 we are able to plot onto
- [00:03:25.847]Figure 6 with various concentrations of
- [00:03:32.008]Glibenclamide on the x-axis vs 1over the
- [00:03:35.938]retention factor and using Equation 1 we
- [00:03:39.619]can calculate its equilibrium constant in
- [00:03:44.805]HSA modified- AGEs- control and diabetic
- [00:03:48.655](methylglyoxal and glyoxal) shown in
- [00:03:52.511]Table 1.
- [00:03:55.373]In table 1, the normal HSA has a greater
- [00:03:58.247]binding constant when compared to control
- [00:04:01.468]diabetic glyoxal and control diabetic
- [00:04:05.127]methylglyoxal. In Figure 7, we see the
- [00:04:10.137]decrease when comparing any of the HSA
- [00:04:15.627]modified forms back to normal HSA.
- [00:04:20.658]The conclusion overall of this experiment
- [00:04:23.715]is the high performance affinity
- [00:04:25.766]chromatography zonal competition studies
- [00:04:28.191]were used to examine the interaction of
- [00:04:30.663]Glibenclamide binding with normal and AGE-
- [00:04:35.520]modified HSA at Sudlow sites I and II.
- [00:04:39.178]The global affinity constants for the
- [00:04:42.764]interaction of Glibenclamide with normal
- [00:04:45.163]HSA and AGE-modified HSA are calculated
- [00:04:49.263]using Equation 1 and shown in Table 1.
- [00:04:56.556]There was an overall 0.25 to 0.39 fold
- [00:05:01.026]changes when comparing normal HSA
- [00:05:03.766]constants to one of the modified forms
- [00:05:07.326]of the protein, as shown in Figure 7.
- [00:05:11.500]This study demonstrated that drug-protein
- [00:05:14.110]interactions can be used to estimate
- [00:05:16.355]binding constants in a relatively fast
- [00:05:19.073]and reproducible way.
- [00:05:21.144]I would like to acknowledge the
- [00:05:25.144]Department of Chemistry at University
- [00:05:28.039]of Nebraska-Lincoln and Queensborough
- [00:05:30.319]Community College. And I also like to
- [00:05:33.200]acknowledge Dr. Mark Griep and Dr. David
- [00:05:36.830]Hage and also Dr. Paris Svoronos and the
- [00:05:41.791]National Science Foundation Research
- [00:05:44.667]Experience for Undergraduates. Thank you
- [00:05:47.999]for listening.
The screen size you are trying to search captions on is too small!
You can always jump over to MediaHub and check it out there.
Log in to post comments
Embed
Copy the following code into your page
HTML
<div style="padding-top: 56.25%; overflow: hidden; position:relative; -webkit-box-flex: 1; flex-grow: 1;"> <iframe style="bottom: 0; left: 0; position: absolute; right: 0; top: 0; border: 0; height: 100%; width: 100%;" src="https://mediahub.unl.edu/media/13786?format=iframe&autoplay=0" title="Video Player: Determination of Equilibrium Constants of Glibenclamide-Human Serum Albumin Interactions by High-Performance Affinity Chromatography" allowfullscreen ></iframe> </div>
Comments
0 Comments